Results 21 to 30 of about 169,757 (284)

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options [PDF]

, 2018
The onset of global epigenetic changes in chromatin that drive tumor proliferation and heterogeneity is a hallmark of many forms cancer. Identifying the epigenetic mechanisms that govern these changes and developing therapeutic approaches to modulate ...
Koschmieder, Steffen, Vetrie, David
core   +1 more source

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

New England Journal of Medicine, 2002
BACKGROUND Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.
H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, C. Gambacorti-Passerini, D. Niederwieser, D. Resta, R. Capdeville, U. Zoellner, M. Talpaz, B. Druker, J. Goldman, S. O’Brien, N. Russell, T. Fischer, O. Ottmann, P. Cony-Makhoul, T. Facon, R. Stone, Carole B. Miller, M. Tallman, R. Brown, M. Schuster, T. Loughran, A. Gratwohl, F. Mandelli, G. Saglio, M. Lazzarino, D. Russo, M. Baccarani, E. Morra   +31 more
semanticscholar   +1 more source

Adoptive Immunotherapy in Chimeras with Donor Lymphocytes [PDF]

, 2003
Allogeneic stem cell transplantation has a well-defined indication in the treatment of hematological malignancies. The beneficial immune effect of allogeneic marrow transplantation has long been known, but only recently have methods been developed to ...
Chen, Xiao, Guenther, Wolfgang, Kolb, Hans-Jochem, Ledderose, Georg, Roskrow, Marie, Schleuning, Michael, Schmid, Christoph, Weber, Martin, Woiciechowski, Anja   +8 more
core   +1 more source

Bone Marrow Niche Trafficking of miR-126 Controls Self-Renewal of Leukemia Stem Cells in Chronic Myelogenous Leukemia

Nature Network Boston, 2018
Leukemia stem cells (LSCs) in individuals with chronic myelogenous leukemia (CML) (hereafter referred to as CML LSCs) are responsible for initiating and maintaining clonal hematopoiesis.
Bin Zhang, L. Nguyen, Ling Li, Dandan Zhao, Bijender Kumar, Herman Wu, A. Lin, F. Pellicanò, L. Hopcroft, Yu-Lin Su, M. Copland, T. Holyoake, C. Kuo, R. Bhatia, D. Snyder, H. Ali, A. Stein, Casey J. Brewer, Huafeng Wang, Tinisha McDonald, P. Swiderski, E. Troadec, C. Chen, A. Dorrance, V. Pullarkat, Yate-Ching Yuan, D. Perrotti, N. Carlesso, S. Forman, M. Kortylewski, Ya-Huei Kuo, G. Marcucci   +31 more
semanticscholar   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth

Theranostics, 2017
Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered.
D. Bellavia, Stefania Raimondo, Giovanna Calabrese, Stefano Forte, M. Cristaldi, Agostina Patinella, Lorenzo Memeo, Mauro Manno, S. Raccosta, P. Diana, G. Cirrincione, G. Giavaresi, F. Monteleone, Simona Fontana, G. De Leo, Riccardo Alessandro   +15 more
semanticscholar   +1 more source

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

Case Reports in Cardiology, 2018
Decitabine is a pyrimidine analogue of nucleoside cytidine, used for the treatment of myelodysplastic syndromes, chronic myelogenous leukemia, and acute myelogenous leukemia.
Pradyumna Agasthi, Hemalatha Narayanasamy, Dan Sorajja, James Slack, Farouk Mookadam   +4 more
doaj   +1 more source

Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia [PDF]

, 2001
Chronic myeloid leukemia (CML) is characterized by formation of the BCR-ABL fusion gene, usually as a consequence of the Philadelphia (Ph) translocation between chromosomes 9 and 22.
Bench, AJ, Campbell, LJ, Grace, C, Green, AR, Huntly, BJP, Nacheva, EP, Prince, HM, Reid, AG, Shepherd, P, Szer, J, Telford, N, Turner, P   +11 more
core   +1 more source

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Blood, 2016
Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic myelogenous leukemia (CML) is generally associated with decreased response to tyrosine kinase inhibitor (TKI) therapy and adverse survival.
Wei Wang, J. Cortes, G. Tang, J. Khoury, Sa A. Wang, C. Bueso-Ramos, Joseph A. DiGiuseppe, Zi Chen, H. Kantarjian, L. Medeiros, Shimin Hu   +10 more
semanticscholar   +1 more source

Chronic Myelogenous Leukemia [PDF]

Laboratory Medicine, 2000
Chronic myelogenous leukemia (CML) is the most common and best studied of the chronic myeloproliferative disorders, resulting from a characteristic Philadelphia chromosomal abnormality, t(9;22)(q34q11). The molecular consequence of this chromosomal translocation is production of a hybrid BCR-ABL (breakpoint cluster region–Abelson leukemia virus) fusion
Daniel A. Arber, Karl Gaal
openaire   +2 more sources